Zartra

RSS

imiquimod

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Zartra has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 31/07/2002

Authorisation details

Product details
Name
Zartra
Agency product number
EMEA/H/C/000180
Active substance
imiquimod
International non-proprietary name (INN) or common name
imiquimod
Therapeutic area (MeSH)
Condylomata Acuminata
Anatomical therapeutic chemical (ATC) code
L03AX
Publication details
Marketing-authorisation holder
Laboratoires 3M Santé
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
18/09/1998
Contact address
Laboratories 3M Sante
Boulevard de l'Oise
F-95029 Cergy Pontoise Cedex
France

Product information

11/06/2002 Zartra - EMEA/H/C/000180 -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunostimulants

Therapeutic indication

Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.

How useful was this page?

Add your rating